DeepMed Research

The Gynecologic Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1970-01-01

Employees: 11

Market Cap: -

Website: http://www.gog.org

Clinical Trials

Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-03-17

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00006812

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States

and more 28 locations

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-02-25

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00005026

Locations: 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 44 locations

Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-02-04

Last Posted Date: 2012-01-10

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00020696

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

and more 51 locations

Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Phase 2

Terminated

Conditions: Cervical Cancer

First Posted Date: 2003-11-11

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00006224

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

and more 36 locations

Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

First Posted Date: 2003-11-06

Last Posted Date: 2013-06-24

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00071929

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Mount Carmel West Hospital, Columbus, Ohio, United States
🇺🇸
Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States

and more 35 locations

Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-11-04

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00005046

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 2 locations

Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer

Terminated

Conditions: Ovarian Cancer

First Posted Date: 2003-10-29

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00003794

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

First Posted Date: 2003-10-21

Last Posted Date: 2013-06-24

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00026260

Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-10-15

Last Posted Date: 2013-06-24

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00023699

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

and more 50 locations

Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix

Phase 2

Terminated

Conditions: Cervical Cancer

First Posted Date: 2003-10-08

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00006482

Locations: 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸
Tufts University School of Medicine, Boston, Massachusetts, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

and more 31 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy